Compare LOVE & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOVE | PHAR |
|---|---|---|
| Founded | 1998 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.7M | 1.1B |
| IPO Year | 2018 | N/A |
| Metric | LOVE | PHAR |
|---|---|---|
| Price | $14.52 | $16.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $27.60 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 593.6K | 22.5K |
| Earning Date | 12-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.90 | N/A |
| EPS | ★ 0.46 | 0.00 |
| Revenue | ★ $690,559,000.00 | $362,274,000.00 |
| Revenue This Year | $6.93 | $24.80 |
| Revenue Next Year | $7.52 | $6.84 |
| P/E Ratio | ★ $31.93 | $2,946.57 |
| Revenue Growth | 0.13 | ★ 26.78 |
| 52 Week Low | $11.26 | $7.50 |
| 52 Week High | $28.21 | $18.12 |
| Indicator | LOVE | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 51.06 |
| Support Level | $11.40 | $16.23 |
| Resistance Level | $15.10 | $17.00 |
| Average True Range (ATR) | 0.84 | 0.75 |
| MACD | 0.14 | -0.16 |
| Stochastic Oscillator | 84.35 | 36.44 |
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.